Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer (aNSCLC), bladder cancer (aBCa), and melanoma (aMM): An electronic health records (EHR) study.

被引：2
|
作者：
Sadetsky, Natalia
Chuo, Ching-Yi
Davidoff, Amy J.
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Yale Sch Publ Hlth, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e18194
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18194
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study
    Sadetsky, Natalia
    Chuo, Ching-Yi
    Davidoff, Amy J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (09) : 1233 - 1241
  • [2] ASSESSING MISSING ANTINEOPLASTIC THERAPY PRIOR TO ELECTRONIC HEALTH RECORD (EHR)-DERIVED FIRST LINE OF THERAPY AFTER ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) DIAGNOSIS
    Reiss, S.
    Ascha, M.
    Asfaw, A. A.
    Brake, S.
    Yerram, P.
    VALUE IN HEALTH, 2023, 26 (06) : S406 - S406
  • [3] Semi-automated discovery of real-world patient pathway from US electronic health records: Advanced non-small cell lung cancer (aNSCLC).
    Yang, Fei
    Zhang, Ju
    O'Neill, Tyler J.
    Sharma, Vishakha
    Prime, Matthew Stewart
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Weekly (W) cisplatin (P) and vinorelbine (V) in advanced non-small cell lung cancer (ANSCLC) elderly patients: A phase II study.
    Lippe, P
    Imperatori, L
    Casadei, V
    Guidi, F
    Gattafoni, P
    Consales, DL
    Mattioli, R
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [5] AN ECONOMIC EVALUATION OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) AFTER PRIOR CHEMOTHERAPY IN CHINA
    Hu, S.
    Fan, L.
    Tang, Z.
    Harrison, J. P.
    Hertel, N.
    Penrod, J. R.
    May, J.
    Young, K. C.
    Holdgate, O.
    VALUE IN HEALTH, 2019, 22 : S72 - S72
  • [6] Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study)
    Chouaid, C.
    Levra, M. Giaj
    Corre, R.
    Calvet, C.
    Gaudin, A-F.
    Grumberg, V.
    Jolivel, R.
    Jouaneton, B.
    Assie, J-B.
    Cotte, F-E.
    ANNALS OF ONCOLOGY, 2019, 30 : 521 - 521
  • [7] An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database
    Carrigan, Gillis
    Whipple, Samuel
    Taylor, Michael D.
    Torres, Aracelis Z.
    Gossai, Anala
    Arnieri, Brandon
    Tucker, Melisa
    Hofmeister, Philip P.
    Lambert, Peter
    Griffith, Sandra D.
    Capra, William B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (05) : 572 - 581
  • [8] Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study
    Ulmeanu, Ruxandra
    Antohe, Ileana
    Anisie, Ecaterina
    Antoniu, Sabina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 165 - 167
  • [9] The Development and Assessment of Advanced Cellular Models for the Study of Non-Small Cell Lung Cancer
    Ryan, Sarah-Louise
    Baird, Anne-Marie
    Davies, Anthony
    O'Byrne, Kenneth J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S483 - S483
  • [10] Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States: A contemporary clinical practice patterns study.
    Gondos, Adam
    Paz-Ares, Luis G.
    Saldana, Diego
    Thomas, Marlene
    Mascaux, Celine
    Bubendorf, Lukas
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345